[Form 4] Amicus Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Amicus Therapeutics (FOLD) insider transaction: Simon N.R. Harford, identified as Chief Financial Officer and reporting person, reported a sale of 12,529 shares of Amicus common stock on 08/21/2025 at a reported price of $7.60 per share. After this transaction he is reported to beneficially own 214,898 shares. The Form 4 is signed by an attorney-in-fact on 08/25/2025.

Positive

• Reporting person identified as Chief Financial Officer, providing clarity on insider role
• Transaction disclosed with specific date (08/21/2025), price ($7.60) and share counts
• Form 4 filed and signed (signed by attorney-in-fact 08/25/2025), indicating compliance with Section 16 reporting

Negative

• Insider sale of 12,529 shares was executed, reducing direct holdings
• No explanation for the sale is provided in the filing

Insights

Financial Analyst

TL;DR: CFO sold 12,529 shares at $7.60, leaving 214,898 shares; transaction disclosed on Form 4.

The filing documents a straightforward open-market sale by the Chief Financial Officer on 08/21/2025 for $7.60 per share. The disclosure shows the remaining beneficial holding, enabling investors to update insider-holding registers. There are no derivative transactions or other complex instruments disclosed. The filing does not provide rationale for the sale.

Corporate Governance Expert

TL;DR: Timely Form 4 reporting of an insider sale by the CFO; no additional governance issues disclosed.

The document indicates compliance with Section 16 reporting via a signed Form 4 dated 08/25/2025 that records an 08/21/2025 sale. It identifies the reporting person as the Chief Financial Officer and reports direct beneficial ownership after the sale. The form contains no amendments, derivative activity, or other governance disclosures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harford Simon N.R.

(Last) (First) (Middle)

47 HULFISH STREET

(Street)

PRINCETON NJ 08542

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		F		12,529	D	$7.6	214,898	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Christian Formica, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Amicus (FOLD) Form 4 filed by the CFO report?

The Form 4 reports that CFO Simon N.R. Harford sold 12,529 shares on 08/21/2025 at $7.60 per share and now beneficially owns 214,898 shares.

When was the Amicus Form 4 signed and filed?

The filing bears a signature by an attorney-in-fact dated 08/25/2025.

Does the Form 4 show any derivative transactions for FOLD?

No. Table II for derivative securities is blank; only a non-derivative common stock sale is reported.

What is the reported sale price per share on the Form 4 for FOLD?

The reported transaction price is $7.60 per share.

How many shares does the reporting person beneficially own after the transaction?

The Form 4 reports beneficial ownership of 214,898 shares following the sale.